Halting Disease Progression
in its Tracks

Now enrolling patients in a registrational Phase 3 trial of AVB-500 in platinum-resistant ovarian cancer.

click here for more information

Halting Disease Progression in its Tracks

Now enrolling patients in a registrational Phase 3 trial of AVB-500 in platinum-resistant ovarian cancer.


click here for more information

Pipeline

AVB-500, our lead product candidate targets GAS6/AXL signaling, an important driver of cell migration and invasion in disease.

Patients

Our first clinical focus is recurrent platinum-resistant ovarian cancer, which is often diagnosed when metastasis has already occurred.

Investors

For the latest news, corporate presentation and investor information, visit the investor section of our site.